References
- Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, etal. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788–824. [PubMed Abstract].
- Collard HR, King TEJr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168: 538–42. [PubMed Abstract].
- Kim DS, Collard HR, King TEJr.. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006; 3: 285–92. [PubMed Abstract] [PubMed CentralFull Text].
- Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008; 3: 8. [PubMed Abstract] [PubMed CentralFull Text].
- Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002; 57: 338–42. [PubMed Abstract] [PubMed CentralFull Text].
- Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994; 150: 967–72. [PubMed Abstract].
- Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllärniemi M. Idiopathic pulmonary fibrosis – a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med. 2013; 13: 53. [PubMed Abstract] [PubMed CentralFull Text].
- Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, etal. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011; 66: 462–7. [PubMed Abstract].
- Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, etal. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med. 2015; 15: 92. [PubMed Abstract] [PubMed CentralFull Text].
- European Medicines Agency. Esbriet: European Public Assessment Report (EPAR) – Product Information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf [cited 1 April 2016]..
- Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, etal. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet. 2011; 377: 1760–9. [PubMed Abstract].
- Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, etal. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040–7. [PubMed Abstract].
- Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, etal. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821–9. [PubMed Abstract].
- Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015; 24: 545.
- King TEJr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, etal. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083–92. [PubMed Abstract].
- Tandvårds- och Läkemedelsförmånsverket (TLV). [Dental and Pharmaceutical Benefits Agency]. Decision regarding Esbriet. Available from: http://www.tlv.se/Upload/Beslut_2012/bes120627-esbriet.pdf [cited 28 June 2012].
- Socialstyrelsens Statistikdatabas för läkemedel. Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel [cited 1 April 2016]..
- Vårdprogram för Idiopatisk Lungfibros. Available from: http://www.slmf.se/sites/default/files/VPIL_2013_web_final.pdf [cited 1 April 2016]..
- Rad P, Karlsson C-A, Janson C. Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors. Eur Clin Respir J. 2015; 2: 26915.
- Lungfibrosregistret. Årsrapport 2015 gällande verksamhetsperioden Sept 2014 – Okt 2015. Available from: http://ww.slmf.se/sites/default/files/lungfibrosregistret_arsrapport_2015_web.pdf [cited 1 April 2016]..
- Ferrara G, Carlson L, Palm A, Einarsson J, Olivesten C, Sköld M, (for the Swedish Idiopathic Pulmonary Fibrosis Registry Group) . Idiopathic pulmonary fibrosis (IPF) in Sweden: report from the first year of activity of the Swedish IPF-Registry. Eur Clin Respir J. 2016; 3: 31090.
- Harari S, Caminati A. Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev. 2015; 24: 420–7. [PubMed Abstract].